Company Profile

Advanced Extravascular Systems
Profile last edited on: 12/14/2006      CAGE:       UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1551 Westwood Boulevard1 Suite 110
Los Angeles, CA 90024
Location: Single
Congr. District: 33
County: Los Angeles

Public Profile

With strong ties in to the University of Pittsburgh Biotech center, Advanced Extravascular Systems is currently designing improved extracorporeal specific antibody filters (SAFs). The desired improvements would lead to a new line of SAF's that are able to selectively remove pathogenic antibodies from the bloodstream, without removing beneficial antibodies and other important plasma proteins, and without the need to separate or exchange plasma. Applications of this technology include the prevention of hyperacute rejection following organ transplant and the reduction of tissue damage caused by autoimmune diseases. The primary application of the technology, and the central interest of current research in the lab, is the development and production of SAFs capable of removing anti-A and anti-B blood group antibodies. Such SAFs would play a pivotal role in facilitating ABO-incompatible renal transplants.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2001 2 NIH $847,665
Project Title: Biomedical Device To Remove Anti A and Anti B Antibodies

Key People / Management

  Terry M Schaack

Company News

There are no news available.